Annual report pursuant to Section 13 and 15(d)

Schedule of Investments (Details)

v3.10.0.1
Schedule of Investments (Details) - USD ($)
$ in Thousands
12 Months Ended
Nov. 30, 2018
Nov. 30, 2017
Opening balance $ 1,321 $ (12)
Reclass from short-term receivables * (795) 118
Investments 0 2,429
Share in losses of associated companies (731) (1,214)
Reductions due to the acquisition of CureCell and Atvio 205 0
Ending balance $ 0 $ 1,321